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Abstract Alpha-ketoglutarate (AKG), an endogenous
intermediary metabolite in the Krebs cycle, is a molecule
involved in multiple metabolic and cellular pathways. It
functions as an energy donor, a precursor in the amino acid
biosynthesis, a signalling molecule, as well as a regulator
of epigenetic processes and cellular signalling via protein
binding. AKG is an obligatory co-substrate for 2-oxoglu-
tarate-dependent dioxygenases, which catalyse
hydroxylation reactions on various types of substrates. It
regulates the activity of prolyl-4 hydroxylase, which con-
trols the biosynthesis of collagen, a component of bone
tissue. AKG also affects the functioning of prolyl
hydroxylases, which, in turn, influences the function of the
hypoxia-inducible factor, an important transcription factor
in cancer development and progression. Additionally, it
affects the functioning of enzymes that influence epigenetic
modifications of chromatin: ten–eleven translocation
hydroxylases involved in DNA demethylation and the
Jumonji C domain containing lysine demethylases, which
are the major histone demethylases. Thus, it regulates gene
expression. The metabolic and extrametabolic function of
AKG in cells and the organism open many different fields
for therapeutic interventions for treatment of diseases. This
review presents the results of studies conducted with the
use of AKG in states of protein deficiency and oxidative
stress conditions. It also discusses current knowledge about
AKG as an immunomodulatory agent and a bone anabolic
factor. Additionally, the regulatory role of AKG and its
structural analogues in carcinogenesis as well as the results
of studies of AKG as an anticancer agent are discussed.
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Introduction
Metabolites, small-molecular weight molecules, are the
substrates and products of enzymatic reactions that occur
naturally within cells. Among these substances, there is
alpha-ketoglutarate (AKG; also known as 2-oxoglutarate,
2-oxopentanedioic acid), an endogenous intermediary
metabolite in the Krebs cycle (the citric acid cycle or the
tricarboxylic acid cycle, TCA) (Krebs and Johnson 1980).
For many years, AKG has been an object of interest for
researchers from various fields of science due to its
essential role in several biological processes and its broad
application scope.
AKG is an important biological molecule that plays a key
role in multiple metabolic and cellular pathways. As a Krebs
cycle metabolite, it regulates anabolic and catabolic TCA
products and substrates, thereby regulating amino acid syn-
thesis, ATP production, and reducing equivalent (NAD?/
NADH) generation, which in turn can influence reactive
oxygen species (ROS) levels (Krebs and Johnson 1980). AKG
is also an obligatory co-substrate for 2-oxoglutarate-depen-
dent dioxygenases (2-OGDDs) (McDonough et al. 2010;
Schofield and Zhang 1999), a large group of phylogenetically
conserved enzymes, which catalyse hydroxylation reactions
on various types of substrates including proteins, nucleic
acids, lipids, and metabolic intermediates. These enzymes
require the presence of Fe(II) as a cofactor as well as O2 and
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AKG as co-substrates. In the hydroxylation reaction of the
substrate, one oxygen atom from O2 is attached to a hydroxyl
group in the substrate while the other one is taken up by AKG,
which leads to decarboxylation of AKG and subsequent for-
mation of CO2 and succinate. Ascorbic acid (vitamin C) also
takes part in these reactions by inducing reduction of oxidised
Fe(IV) to Fe(II) and restoring the activity of 2-OGDD
enzymes. In humans, there are more than 60 different
2-OGDDs, and some of these enzymes play a key role in
physiologically important processes such as the hypoxic
response, fatty acid metabolism, nucleic acid repair and
modification, and epigenetic regulation (Hausinger 2004;
Rose et al. 2011). As a substrate of hydroxylases, belonging to
OGDDs, AKG exerts an impact on prolyl/aspartyl/lysyl
hydroxylations, which in turn regulates the stability of the
hypoxia-inducible factor (HIF)-1 and collagen synthesis.
Prolyl hydroxylases PHD1-3 influence the function of HIF-1
(Bruick and McKnight 2001; Epstein et al. 2001; Hirsila¨ et al.
2003), an important transcription factor in cancer develop-
ment and progression, while prolyl-3 and prolyl-4
hydroxylases (P3H, P4H) control the biosynthesis of collagen
(Kivirikko and Pihlajaniemi 1998), a very important com-
ponent of bone tissue. AKG is also a required substrate of the
Jumonji C domain containing lysine demethylases (KDM2-
7), which are the major histone demethylases (Tsukada et al.
2006) and ten–eleven translocation hydroxylases (TET1-3)
involved in DNA demethylation, which catalyse the oxidative
decarboxylation of AKG, generating 5-hydroxy-methylcy-
tosine (5-hmC) and leading to epigenetic effects (Ito et al.
2010; Tahiliani et al. 2009). Moreover, AKG binds and reg-
ulates G protein function, because it is a ligand for the G
protein-coupled receptor (GPR99/GPR80 or OXGR1), which
acts exclusively through a Gq/11-mediated pathway (He et al.
2004). Signalling through this pathway mobilises intracellular
Ca2? (via activation of phospholipase C), which acts as a
diffusible second messenger regulating a wide range of vital
cell functions, including cellular metabolism and growth as
well as cell division and differentiation (Mizuno and Itoh
2009). In this way, AKG can also function as a signalling
molecule. The GPR99 receptor has so far been found in
kidney, placenta, testis, smooth muscles, trachea, and mast
cells (He et al. 2004; Wittenberger et al. 2002), however, its
physiological role has been recently described only in kidney,
where it regulated the acid–base balance in the kidney tubules
in an AKG-dependent manner (Tokonami et al. 2013).
Recently, it has been shown that supplementation of AKG
to adult Caenorhabditis elegans delays ageing of this
nematode. These studies revealed a novel binding protein of
AKG, namely the ATP synthase beta subunit (Chin et al.
2014). This finding suggests that regulatory networks acted
upon by AKG are more complex than it was previously
supposed.
The metabolic and extrametabolic function of AKG in
cells and the organism open many different fields for
therapeutic interventions for treatment of diseases. Meta-
bolism is closely linked with ageing. The main symptoms
of ageing, among others, are disturbances in protein
metabolism and altered bone metabolism. Abnormal pro-
tein metabolism is also observed after trauma (Engel et al.
2003), surgery (Vinnars et al. 1975), burns (Biolo et al.
2000), or infections (Askanazi et al. 1980). Given its
metabolic properties, AKG may be useful in reducing this
type of disorders. Moreover, altered metabolism is a fea-
ture of cancer cells (Jeong and Haigis 2015). Evidence
from recent years has shown that the mitochondrial genes
of Krebs cycle enzymes may function as oncogenes or
tumour suppressors by influencing different cellular pro-
cesses. Genes encoding succinate dehydrogenase (SDH)
and fumarate hydratase (FH) act as tumour suppressors
(Astuti et al. 2001; Baysal et al. 2000; Burnichon et al.
2010; Castro-Vega et al. 2014; Tomlinson et al. 2002).
Mutations thereof lead to accumulation of succinate and
fumarate, structural analogues of AKG and oncometabo-
lites, which have a tumourigenic role by inhibiting the
activity of PHD enzymes and inducing pseudo-hypoxia
(Pollard et al. 2005). In contrast, isocitrate dehydrogenase
(IDH1/2) genes (products of which catalyse the oxidative
decarboxylation of isocitrate to AKG) act as oncogenes
(Amary et al. 2011; Borger et al. 2012; Mardis et al. 2009;
Parsons et al. 2008). Mutations in these genes lead to
production of changed enzymes, which reduce AKG to
another oncometabolite—R(-)-2-hydroxyglutarate (2HG)
(Dang et al. 2009). All the oncometabolites mentioned
above modulate (inhibit) the activity of PHD, TET, and
KDM enzymes and in this way they participate in the
pathogenesis of many cancers. In this case, AKG could be
used for reactivation of 2-OGDD enzymes and reversal of
metabolic alterations (Fig. 1).
The Formation of AKG in the Krebs Cycle and its
Metabolism
AKG is a key intermediate in the TCA cycle, the energy-
producing process that occurs in cells. TCA is a cyclic
pathway of eight enzymatic reactions, which oxidises
compounds derived from glucose, fatty acids, and amino
acids in the matrix of mitochondria, leading to formation of
CO2 and reduced coenzymes (NADH and FADH2). These
coenzymes feed electrons to the respiratory chain further
used to generate ATP. In the TCA cycle, AKG is formed
from isocitrate by oxidative decarboxylation catalysed by
IDH. It can be further converted by AKG dehydrogenase to
succinyl-CoA and NADH (Krebs and Johnson 1980).
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The amount of AKG produced in mitochondria depends
on the state of oxidation–reduction (redox). The advantage
of NAD? over NADH leads to oxidative decarboxylation
of AKG and formation of succinyl-CoA, while in the case
of an increased concentration of NADH and a shortage of
NAD?, reductive transamination of AKG takes place with
the participation of glutamate dehydrogenase, leading to
formation of glutamate (Owen et al. 2002). Glutamate
formed in this reaction can then, in the reaction involving
glutamine synthetase, attach another ammonium ion, which
results in formation of glutamine (Krebs 1935). AKG can
also be produced in the reaction of glutamate and pyruvate
catalysed by glutamate pyruvate transaminases (GPT1/2).
Additionally, the reversible transfer of an amino group
(NH3
?) from glutamate to oxaloacetate also results in the
formation of AKG (and aspartate). This reaction is catal-
ysed by glutamate oxaloacetate transaminase, which exists
in cytoplasmic and inner-membrane mitochondrial forms,
GOT1 and GOT2, respectively (Yudkoff et al. 1994; for
review see Sookoian and Pirola 2015).
The TCA cycle metabolites can penetrate to the cyto-
plasm, where they can be used as precursors for
biosynthetic reactions. AKG can freely diffuse through
channels (such as voltage-dependent anion channels) in the
outer mitochondrial membrane, and it is transported across
the inner mitochondrial membrane through the oxoglu-
tarate carrier (OGC), also known as an oxoglutarate/malate
antiporter. The OGC plays an important role in the malate-
aspartate shuttle and the oxoglutarate-citrate (isocitrate)
shuttle (Chappell 1968; for review see Monne´ et al. 2013;
Palmieri et al. 1972).
Because AKG is a key intermediate in the Krebs cycle,
it is mainly found in cells (in mitochondria and cytoplasm),
but it can also be detected in small quantities (lM) in the
bloodstream (Martin et al. 1989; Rocchiccioli et al. 1984;
Wagner et al. 2010). However, in people over 40 years of
Fig. 1 Schematic representation of the pleiotropic activity of the
AKG molecule. Alpha-ketoglutarate is a precursor of glutamine
which contributes to muscle repair, prevents protein catabolism,
improves nitrogen retention, functions as an immunomodulatory
molecule, and takes part in proper function of intestines. AKG is also
involved in cell protection against oxidative stress and cyanide
poisoning. It can also influence bone strength and density and inhibit
carcinogenesis induced by oncometabolites or hypoxia by activating
enzymes from the 2-OGDD family (2-oxoglutarate-dependent dioxy-
genases). Their action involves epigenetic regulation such as histone
and DNA demethylation carried out by KDM 2–7 (Jumonji C domain
containing lysine demethylases) and TET 1–3 (10–11 translocation
hydroxylases), respectively, and non-epigenetic regulation, which
includes activation of prolyl hydroxylases: P4H (prolyl 4-hydroxy-
lase) involved in type I collagen biosynthesis and PHD2 (prolyl
hydroxylase domain-containing protein 2) responsible for hydroxy-
lation and thus inactivation of HIF-1a (hypoxia-inducible factor).
Other cofactors for the 2-OGDD enzymes are Fe2?, O2, and ascorbate
while their inhibitors known as oncometabolites include succinate,
fumarate, and 2-HG (R(-)-2-hydroxyglutarate)
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age its level is gradually reduced (to the quantity of ng/ml)
(Harrison and Pierzynowski 2008). Presumably, AKG
present in blood may derive from the bacterial flora
inhabiting the intestine, as different bacteria secrete this
metabolite (Otto et al. 2011). Interestingly, physiological
increases in AKG levels have been observed in the blood of
humans after physical exercise (Brugnara et al. 2012), in
the liver of starved pigeons (Kaminsky et al. 1982), and in
starved C. elegans (Chin et al. 2014).
AKG is an important intermediate in the biosynthesis of
amino acids. Cataplerotic reactions that prevent the accu-
mulation of excess AKG in the cell are associated with
production of two amino acids: glutamate and glutamine,
which are very important for energy metabolism. These
two amino acids play a key role in many metabolic path-
ways and determine proper functioning of organs such as
kidney, intestine, liver, as well as pancreatic b cells, neu-
rons, and cells of the immune system (Newsholme et al.
2003).
In various physiological and pathological states, the
body may experience an increase in protein catabolism. In
these states, glutamine from the muscle and lung tissue is
released and becomes available to other organs (such as the
intestine or kidneys) and to immune cells. To increase its
levels in the body and thus reduce the catabolic response,
or even increase protein anabolism, a relevant clinical
nutrition therapy (enteral and parenteral) is applied (Stehle
et al. 1989). However, the use of glutamine in such a
therapy has not found widespread use in medicine, due to
the instability of aqueous solutions of this amino acid.
Nowadays glutamine supplementation in parenteral nutri-
tion is indicated primarily for patients in critical conditions
(Al Balushi et al. 2013; Stein et al. 2009). Similarly, glu-
tamate, from which glutamine can be synthesised de novo,
is not routinely used in nutritional therapy because of its
relative neurotoxicity and poor permeability across cell
membranes (Hermanussen and Tresguerres 2005). In con-
trast, as an exogenous glutamine precursor that can be used
in many deficiency states, AKG has been an object of
interest for researchers and clinicians for many years.
Many in vivo studies (Cynober et al. 1984, 1990; Da˛bek
et al. 2005; Filip and Pierzynowski 2008; Junghans et al.
2006; Loı¨ et al. 2005) demonstrate that exogenous AKG
administered as a dietary supplement in the form of various
salts (ornithine, sodium, calcium) is absorbed by the
organism and can be metabolised to glutamine and gluta-
mate as well as to other amino acids (proline, arginine).
Experimental studies performed on animals have shown
that ingested AKG, glutamine, and glutamate are absorbed
in the upper small intestine and then metabolised in ente-
rocytes. During the first pass metabolism in the intestinal
mucosa, up to 95 % of glutamate, 70 % of glutamine, and
only 40 % of AKG is degraded to CO2 (Junghans et al.
2006). The remaining part of AKG may be used in various
anabolic pathways, both in the enterocytes and in periph-
eral tissues, because up to 20 % of dietary AKG appears in
the bloodstream (Filip and Pierzynowski 2008). After
absorption, this part of AKG can be used for the synthesis
of amino acids such as glutamine or proline. AKG is
rapidly removed from the bloodstream, and its half-life is
less than 5 min (Cynober et al. 1990; Da˛bek et al. 2005).
The circulating AKG is passed to the liver and kidney
using a sodium–potassium pump (Stoll et al. 1991; Wel-
born et al. 1998). Cell culture experiments have
demonstrated that AKG can be easily passed to fibroblasts
by simple diffusion (Aussel et al. 1996). However, the
other cell culture research suggests that the ability of AKG
to penetrate cells is relatively weak but can be increased by
the use of its esters (Koivunen et al. 2007; MacKenzie et al.
2007). AKG is fully metabolised by the body and no
excretion of the compound in the pure form with urine or
faeces is observed. Studies with the sodium salt of 14C-
labelled AKG revealed the presence of AKG carbon in
several tissues (liver, brain, skin, muscle, bone tissue)
already after 3 h of administration of the compound (Filip
and Pierzynowski 2008).
AKG and Protection of Cells Against Oxidative
Stress
Free radicals also known as ROS are important mediators
in cell damage and cell death processes (Sena and Chandel
2012). They are involved in a variety of pathological
conditions, attacking various cellular macromolecules.
ROS can cause peroxidation of lipids forming cell mem-
branes, structural and functional changes in proteins, or
even damage to nucleic acids. Literature data suggest that
in different cases of induced oxidative stress under in vitro
or in vivo conditions, AKG, like some other metabolites of
the Krebs cycle, has antioxidant properties (Andrae et al.
1985). AKG may participate in non-enzymatic oxidative
decarboxylation during the decomposition of hydrogen
peroxide, which is conditioned by its chemical structure
(Long and Halliwell 2011; Sokołowska et al. 1999; Vel-
vizhi et al. 2002a, b; Yamamoto and Mohanan 2003). It has
also been shown that AKG can prevent damage to mito-
chondrial DNA induced by free radicals in mouse neural
cells (Yamamoto and Mohanan 2003). Furthermore, AKG
inhibited oxidative stress induced in vivo in rats by
administration of ammonium acetate or ethanol (Velvizhi
et al. 2002a, b). Additionally, it has been detected that
AKG administration positively modulates antioxidant
levels in rats during induced hepatocarcinogenesis, restor-
ing antioxidants as well as antioxidative enzyme activity to
almost normal levels (Dakshayani et al. 2006). In another
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in vivo study (Varma and Hegde 2004), AKG had a pro-
tective effect against oxidative stress-related cataract
formation induced by injection of sodium selenite to rat
pups.
One of the most interesting features of AKG is its
antagonist activity against cyanogens, i.e., materials con-
taining nitriles from which human organism can generate
free cyanide at a level that is toxic to the body. Cyanogens
may occur naturally or they can be synthetically manu-
factured; they can be found in various industrial products,
household utensils, or even in certain medications (Bhat-
tacharya et al. 2009). Cyanide (hydrocyanic acid salt) is a
rapidly acting neurotoxin, the operation of which is related
to, among others, induction of oxidative stress in neurons,
formation of ROS, and inhibition of the activity of a
number of metalloenzymes including the antioxidant
enzyme system (Ardelt et al. 1989, 1994; Muller and
Krieglstein 1995; Solomonson 1981). The action of cya-
nide in the cell leads to impaired mitochondrial activity, as
a result of which cellular respiration and energy metabo-
lism is inhibited, which finally causes lactic acidosis and
cell death (Bhattacharya et al. 2009; Hariharakrishnan et al.
2009). As has been shown, AKG acts as an antagonist of
cyanide poisoning, and its protective effect involves, e.g.,
binding cyanide by a keto group attached to the carboxylic
carbon of AKG, which leads to formation of an interme-
diate—cyanohydrin (Moore et al. 1986; Norris et al. 1990).
Furthermore, AKG prevented cyanide-induced reduction in
the level of glutathione (an important antioxidant of the
cell) and DNA fragmentation in rat thymocytes cultured
in vitro (Bhattacharya et al. 2002). Moreover, AKG is
known to have protected the brain and liver of rats from
damage caused by cyanide-induced ROS activity, and the
addition of sodium thiosulphate increased its protective
effect (Tulsawani et al. 2005). It also showed the ability to
neutralise the oxidative stress caused by cyanogens
(Bhattacharya et al. 2009).
Recent studies have shown that the AKG molecule
modulates the activity of antioxidant enzymes and sta-
bilises the oxidation–reduction homeostasis in mice of
advanced age to the level observed in young animals
(Niemiec et al. 2011).
AKG as a Complementary Factor in States
of Protein Deficiency: Clinical and Animal Studies
As a precursor of glutamine, AKG is a molecule with high
potential in the treatment of states with increased protein
catabolism, such as recovery after trauma, severe infections
and burns, or after surgeries. In a number of independent
clinical studies, attempts have been made to use exogenous
AKG in alleviating this type of disorders by introducing
supplementation mainly with an ornithine salt of alpha-
ketoglutarate (OKG), consisting of two molecules of
ornithine and one molecule of AKG. It has been shown that
such a combination is more efficient than AKG or ornithine
alone in restoring glutamine pools in muscles (Cynober
et al. 2007). The mechanism of OKG action in the body is
still unclear, but it is probably multifactorial. OKG activity
is associated with an increased synthesis of glutamine,
proline, arginine, polyamines as well as with its capacity to
induce secretion of anabolic hormones (insulin, growth
hormone) and probably with elevated production of nitric
oxide from arginine (Cynober 2004). Many studies (Cou-
dray-Lucas et al. 2000; De Bandt et al. 1998; Donati et al.
1999; Hammarqvist et al. 1989, 1990, 1991; Wernerman
et al. 1987) showed that OKG administered orally, enter-
ally, or parenterally improved protein metabolism in
patients with chronic or acute protein deficiency. Addi-
tionally, OKG administration improved nitrogen balance of
the body and decreased protein catabolism by reducing
muscle proteolysis in patients with severe burns (Coudray-
Lucas et al. 2000; De Bandt et al. 1998; Donati et al. 1999),
after surgery (Hammarqvist et al. 1989, 1991; Wernerman
et al. 1987), trauma, or acute infections (Coudray-Lucas
et al. 2000; De Bandt et al. 1998; Donati et al. 1999;
Hammarqvist et al. 1990). In patients with burns, admin-
istration of OKG also accelerated wound healing (Coudray-
Lucas et al. 2000; De Bandt et al. 1998; Donati et al. 1999).
OKG also helped to restore metabolic balance by stimu-
lating the secretion of anabolic hormones—insulin, growth
hormone (GH), and insulin-like growth factor (IGF)-1 in
patients after trauma (Jeevanandam and Petersen 1999).
The introduction of OKG supplementation in malnourished
patients of advanced age resulted in a significant
improvement in their overall health expressed by increased
appetite and improved motor skills; it also shortened the
time of recovery after severe illnesses or surgery (Blonde-
Cynober et al. 2003; Brocker et al. 1994).
Also, many studies on animals with induced muscle
catabolism (Jeevanandam et al. 1996; Le Boucher et al.
1997; Se´gaud et al. 2005; Vaubourdolle et al. 1988, 1991)
showed that OKG modulated protein metabolism by
decreasing urea excretion, increasing protein synthesis in
the liver and the intestine, and by inhibiting the degradation
of myofibrils, reducing total proteolysis, and loss of glu-
tamine from muscle tissue. In addition, OKG exerted a
positive effect on the functioning of the intestinal mucosa
and contributed to its recovery after surgery (Czernichow
et al. 1997; Dumas et al. 1988; Raul et al. 1995). Studies
performed on rats have shown that OKG also improves
motor skills in healthy individuals (Moinard et al. 2004). It
is also known to protect liver cells against damage and
prevent a decrease in the activity of the cytochrome P-450
family produced in liver (Roch-Arveiller et al. 1999).
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Moreover, recent studies have shown that AKG can alle-
viate intestinal mucosa injury under inflammatory
conditions and enhance protein synthesis in intestinal
epithelial cells (Hou et al. 2011; Yao et al. 2012).
AKG as an Immunomodulatory Agent
Glutamine is a known immunoenhancing nutrient in vivo
and a modulator of immune cell growth and function
in vitro (Abcouwer 2000; Andrews and Griffiths 2002;
Saito et al. 1999; Ziegler and Daignault 2000). It modulates
the function of monocytes and neutrophils (by increasing
phagocytosis and ROS intermediate production) and mac-
rophages (by enhancing cytokine production) involved in
the early, non-specific defence response (Furukawa et al.
1997, 2000; Ogle et al. 1994; Wells et al. 1999). Addi-
tionally, glutamine is also a fuel for lymphocyte functions
(Ardawi 1988) enhancing their proliferation and production
of intracellular ROS and glutathione (Chang et al. 1999a)
or cytokines (Chang et al. 1999b; Kew et al. 1999). It has
been shown that AKG, as a glutamine homologue, has
immune-enhancing properties as well, influencing both the
non-specific and the specific immune response, especially
in stress situations. Studies on rats with burn injures
demonstrated that OKG (ornithine alpha-ketoglutarate)
displays immunomodulatory properties, because it coun-
teracted the decrease in superoxide anion (O2
-) generation
in polymorphonuclear leukocytes (PMNs) from these ani-
mals (Roch-Arveiller et al. 1996). Moreover, in other
in vivo studies, OKG enhanced the intracellular production
of hydrogen peroxide (H2O2) and O2
- in PMNs and
monocytes isolated from rats with induced catabolism,
which confirmed that OKG can improve phagocyte
response during stress (Moinard et al. 1999, 2002). Addi-
tionally, it has been shown that OKG can enhance
macrophage cytotoxicity in stress situations by restoring
tumour necrosis factor-a secretion and increasing nitric
oxide production in stimulated macrophages (Moinard
et al. 1999, 2000). Also, exogenous AKG increased O2
-
and H2O2 intracellular production as well as myeloperox-
idase activity in PMNs in vitro (Mu¨hling et al. 2010).
Furthermore, OKG counteracted thymic involution (which
is classically associated with a decreased thymocyte count)
in burn injured rats and increased tissue concentrations of
glutamine and arginine, two essential nutrients for acti-
vated immune cells (Le Boucher et al. 1999). OKG can
also stimulate various mechanisms of the immune system
to an anti-tumour response. It was observed that OKG
administered as a dietary supplement to rats with tumours
increased the cytostatic activity of macrophages and the
cytotoxic activity of natural killer cells (Robinson et al.
1999).
The Influence of AKG on Bone Tissue
In recent years, numerous papers (Dobrowolski et al. 2008;
Filip et al. 2007; Filip 2007; Harrison et al. 2004; Radzki
et al. 2012; Tatara et al. 2005, 2006, 2007) have been
published to suggest that AKG may have an anabolic effect
on bone tissue. Many in vivo studies (Harrison et al. 2004;
Tatara et al. 2006, 2007) have demonstrated that supple-
mentation of AKG or its derivatives during the animal
growth has positive effects on the development of skeleton
by improving the mechanical properties of skeletal bone.
Moreover, other in vivo studies have shown that AKG
supplementation prevented the development of osteopenia
in female ovariectomized rats (Radzki et al. 2012), in rats
after gastrectomy (Dobrowolski et al. 2008) or in model of
osteopenia induced by denervation in turkeys (Tatara et al.
2005). In a study of menopausal women, it was also
observed that administration of AKG (with Ca) inhibited
bone resorption and reduced the effects of osteopenia. In
women treated with AKG sodium salt, after 24 weeks of
treatment, a significant decrease (about 37 %) in the level
of CTX in the bloodstream was observed as well as higher
bone density of the lumbar spine in comparison with the
control group (receiving only CaCO3) (Filip et al. 2007).
The results of above studies suggest that AKG not only can
inhibit bone resorption, but can also induce reconstruction
of bone tissue in the states of osteopenia and osteoporosis.
Although the positive influence of AKG on bone min-
eral density and strength is well documented in many
in vivo studies (Dobrowolski et al. 2008; Filip et al. 2007;
Harrison et al. 2004; Radzki et al. 2012; Tatara et al.
2005, 2006, 2007), its mechanism has not been elucidated
so far. It is believed that AKG can contribute to an increase
in the body pool of amino acids necessary for synthesis of
type I collagen (proline and hydroxyproline) and thus have
a positive effect on bone quality (Harrison and Pierzy-
nowski 2008; Majamaa et al. 1987; Petersen et al. 2003).
Some of the results of studies conducted in vivo in humans
and animals (Cynober et al. 1990; Jeevanandam and
Petersen 1999; Kristensen et al. 2002; Riedel et al. 1996;
Tatara et al. 2005, 2006), where it was observed that OKG
or AKG sodium salt led to an increase in the serum levels
of proline, may be used as a support of this thesis. It is also
suggested that AKG can stimulate production of IGF-1 or
GH, which are anabolic hormones that regulate bone
modelling and remodelling. IGF-1 increases the efficiency
of mature osteoblasts by, among others, stimulating colla-
gen synthesis and inhibiting degradation thereof, while GH
stimulates proliferation of the osteoblastic cell line and
increases the expression of bone morphogenetic proteins,
which stimulate osteoblast differentiation and bone for-
mation (Giustina et al. 2008). Moukarzel et al. (1994)
26 Arch. Immunol. Ther. Exp. (2017) 65:21–36
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showed that parenteral administration of OKG increased
the circulating plasma level of IGF-1, which was confirmed
by another study (Jeevanandam and Petersen 1999) carried
out on grown-ups who were orally supplemented with
OKG and in whose circulating blood the levels of IGF-1
and GH were increased. Furthermore, it was demonstrated
(Tatara et al. 2012) that oral administration of AKG in
combination with beta-hydroxy-beta-methylbutyrate for
pregnant sows increased the serum concentration of GH
and IGF-1 in their offspring. However, in the studies of
Harrison et al. (2004), in which a group of lambs were
supplemented with sodium salt of AKG, no increase in
IGF-1 plasma levels was observed, yet there was an
increase in their bone mineral density. In turn, other in vivo
studies (Harrison et al. 2004; Rosen et al. 1995) have
demonstrated that IGF-1 stimulates bone growth and
increases their size, but does not affect the mineral density.
These findings suggest that the positive effect of AKG on
bone tissue is probably not associated with stimulation of
IGF-1 and GH production when it is administered alone.
The positive effect of AKG on bone tissue may be due to
its important role in the biosynthesis of glutamate and
glutamine, as well as a multidirectional impact on the
synthesis of type I collagen, the main protein of the bone
matrix. AKG can participate in the metabolism of bone
collagen by various mechanisms. First of all, this
metabolite regulates the activity of enzyme P4H, as men-
tioned above, a member of the 2-OGDDs family,
commonly present in various types of cells. P4H occurs
inside the endoplasmic reticulum and controls the synthesis
of collagen by hydroxylation of proline to 4-hydroxypro-
line (Hutton et al. 1966; Kivirikko and Pihlajaniemi 1998),
which is necessary to form a triple helix of the collagen
molecule. Incomplete hydroxylation of proline in the Gly-
X-Y sequence results in incorrect formation of the collagen
triple helix. Such defective collagen molecules, contrary to
the proper ones, are degraded in the endoplasmic reticulum
instead of being secreted into the cytoplasm (Lamande´ and
Bateman 1999; Myllyharju 2003). AKG can also partici-
pate in the biosynthesis of collagen by increasing the pool
of proline, an amino acid that is the main component of the
collagen molecule. The primary source of proline used for
biosynthesis of collagen are the products of endogenous
and exogenous collagen degradation (Jackson et al. 1975).
Proline may also be formed by conversion of AKG to
glutamate, and then to pyrroline-5-carboxylate (P5C),
which is converted directly into proline (Smith et al. 1980).
However, this pathway is less important in acquiring a pool
of proline needed for collagen biosynthesis. It is more
important that its precursor, i.e. P5C affects the activity of
prolidase, an enzyme responsible for cleavage of dipeptides
containing C-terminal proline or hydroxyproline and
thereby creating a pool of amino acids required for the
biosynthesis of collagen (Myara et al. 1984). Karna et al.
(2001) have shown in their study that P5C indeed stimu-
lates the production of collagen through activation of
prolidase. Therefore, as a precursor of P5C, AKG can
significantly affect the metabolism of proline. The contri-
bution of AKG in the biosynthesis of collagen was
confirmed in in vitro studies, in which it stimulated the
synthesis of procollagen in human skin fibroblasts by
increasing the activity of prolidase (Son et al. 2007).
Additionally, in vivo studies (Son et al. 2007) have
demonstrated a protective effect of AKG on UVB-irradi-
ated skin, since administration thereof to the skin of mice
irradiated with UVB reduced the number of wrinkles and
decreased the degree of collagen fibre destruction in the
skin.
AKG as an Anticancer Agent
So far, not many investigations of the anticancer activity of
AKG have been carried out (Brie`re et al. 2005; Hou et al.
2014; MacKenzie et al. 2007; Matsumoto et al. 2006, 2009;
Robinson et al. 1999; Rzeski et al. 2012; Tennant et al.
2009). However, the results of those few available papers
suggest anti-tumour properties of AKG under both normal
and reduced oxygen levels and interference of its activity
with various mechanisms.
The Role of AKG in the Regulation of HIF-1
Activity
Recent research suggests that AKG and its structural ana-
logues (succinate, fumarate) are involved in the regulation
of signalling pathways engaged in promotion of carcino-
genesis (for review see Raimundo et al. 2011).
PHDs 1-3 which catalyse the hydroxylation of proline
residues are very important enzymes belonging to the
2-OGDD group. They are known to regulate the activity of
HIFs, which play a major role in carcinogenesis, inducing
changes in the metabolism of cancer cells (Bruick and
McKnight 2001; Epstein et al. 2001; Hirsila¨ et al. 2003;
Jaakkola et al. 2001; Maxwell et al. 2001). The best
characterised enzyme of this group is PHD2 (prolyl
hydroxylase domain-containing protein 2), encoded by the
gene EGLN1, which is proposed to be the most important
in the hypoxic response under normoxia (Appelhoff et al.
2004; Berra et al. 2003; Schofield and Ratcliffe 2005).
AKG-dependent dioxygenases can potentially be sensitive
to the slightest changes in cellular concentrations of this
metabolite. This is related to the fact that the Michaelis
constant (Km) of AKG for many dioxygenases is similar to
the physiological concentration of this ketoacid (Clifton
et al. 2006; Loenarz and Schofield 2008). In addition, the
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enzymes responsible for the formation of AKG (IDH-1, -2,
-3), and for its further processing (AKG dehydrogenase,
glutamate dehydrogenases) are strictly controlled.
During the development of solid tumours, large areas
with considerable hypoxia are formed. In response to
hypoxia, there is a change in the metabolism of cancer
cells, enabling them to survive and adapt to the changed,
highly stressful microenvironment. Metabolic changes
include, among others, intensified glycolysis, increased
glycogen synthesis, and use of glutamine (rather than
glucose) as the primary substrate for fatty acid synthesis.
This metabolic reprogramming is directed at the tran-
scriptional level by the transcription factor HIF-1, which
also induces the expression of genes regulating the process
of angiogenesis and cell proliferation (Semenza 2013).
There are two types of HIF (HIF-1 and HIF-2) in
mammalian cells. Each of them is a heterodimer consisting
of one subunit a, which is O2-labile, and one stable subunit
b. There are three known isoforms of subunit a: HIF-1a,
HIF-2a, and HIF-3a. The first one (HIF-1a) is constitu-
tively expressed in all cells, while the other two isoforms
(HIF-2a and HIF-3a) are expressed only in certain tissues
(including endothelial, lung, renal, and liver cells, as well
as the cells of the myeloid lineage). The HIF-3a subunit
functions as a dominant negative regulator of HIF-2a and
HIF-1a, because by binding to subunit b, it blocks its
binding to DNA (Kaelin and Ratcliffe 2008; Maynard et al.
2005; Wiesener et al. 2003). Under aerobic conditions,
proline residues (Pro402 and Pro564) located in the oxy-
gen-dependent degradation domain of HIF-1a are
hydroxylated by PHD2, which results in recognition of the
subunit by the VHL protein (von Hippel-Lindau tumour
suppressor), a part of the ubiquitin ligase complex E3.
Then, after poly-ubiquitination, HIF-1a is rapidly degraded
in the proteasome (Ivan et al. 2001; Kaelin 2005; Yu et al.
2001). Under the oxygen deficiency conditions or at
reduced levels of AKG or Fe2?, the hydroxylation reaction
involving PHD2 slows down or stops, resulting in HIF-1a
accumulation in the cytoplasm (Schofield and Ratcliffe
2005). After the translocation into the cell nucleus, HIF-1a
dimerises with a stable HIF-1b subunit and the dimer
recognises and binds to hypoxia response elements in the
genome (Kaelin 2005).
The Role of Defects in the Krebs Cycle Enzymes
in the Regulation of HIF-1 Activity
As mentioned above, under physiological conditions, HIF-
1 is activated by hypoxia. However, this factor may also be
activated in normal oxygen access, and activation of the
HIF-1-mediated response pathway in such conditions is
referred as pseudohypoxia. Stabilisation of the HIF-1a
subunit occurs, e.g., in the case of a deletion or inactivating
mutation in the gene for the VHL protein, which deter-
mines the development of tumours, such as human
glioblastoma or sporadic renal cell carcinoma (Latif et al.
1993; Ohh 2006; Pugh and Ratcliffe 2003). Also, mutations
in the genes for enzymes involved in the metabolism of
AKG, which is a cofactor of PHDs, result in stabilisation of
the HIF-1a subunit. These mutations occur mainly in three
enzymes of the Krebs cycle: SDH, FH, and IDH.
SDH is a heterotetramer complex localised in mito-
chondria and composed of subunits A, B, C, and D and the
SDH5 factor involved in tetramer mounting (Hao et al.
2009). It has been demonstrated that mutations occurring in
the individual components of the complex may predispose
to the development of certain types of cancer, mainly
paragangliomas (Astuti et al. 2001; Baysal et al.
2000, 2002; Burnichon et al. 2010; Niemann and Muller
2000), pheochromocytomas (Astuti et al. 2001), renal cell
carcinoma (Ricketts et al. 2008; Vanharanta et al. 2004), T
cell acute leukaemia (Baysal 2007), and gastrointestinal
stromal tumours (Italiano et al. 2012; Janeway et al. 2011;
Stratakis and Carney 2009). FH, on the other hand, is an
active homotetramer occurring in the mitochondria and the
cytoplasm, recessive mutations in the gene of which are the
cause of development of encephalopathy and early death,
while its dominant mutations predispose to cancers such as
multiple cutaneous and uterine leiomyomas or hereditary
leiomyomatosis and renal cell cancer (Castro-Vega et al.
2014; King et al. 2006; Tomlinson et al. 2002). Defects in
the SDH and FH enzymes are the cause of accumulation of
Krebs cycle intermediates, i.e., succinate and fumarate
(structural analogues of AKG) in cells. These compounds
compete with AKG in binding to PHD2, and when bound
to the enzyme they inhibit its activity, which in turn con-
tributes to stabilisation of HIF-1a and activation of genes
that promote carcinogenesis (Brie`re et al. 2005; Isaacs et al.
2005; Pollard et al. 2005; Pugh and Ratcliffe 2003; Selak
et al. 2005).
Mutations in the genes of IDH1 and IDH2 may also
affect the activity of HIF-1 (Zhao et al. 2009). NADP?
dependent enzymes, IDH1 and IDH2, are homodimers,
wherein IDH1 is present in the cytoplasm and peroxisomes,
and IDH2 in cell mitochondria (Corpas et al. 1999). It has
been shown that mutations in IDH1 and IDH2 are
responsible for the development of certain cancer types,
including diffuse and anaplastic gliomas, secondary
glioblastomas, specific types of cartilaginous tumours, and
acute myeloma leukaemia (for review see Dang et al. 2010;
Schaap et al. 2013). The mutated enzymes lose their natural
ability to transform isocitrate into AKG, instead acquiring
the ability to reduce AKG to 2HG. As a result, the pool of
mobile AKG is reduced, and the cell accumulates its
structural analogue—2HG (Dang et al. 2009; Schaap et al.
2013). According to some authors’ reports, both a
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reduction in the amount of AKG and an increase in the
amount of 2HG can inhibit the activity of PHD2 and
activate HIF-1 (Xu et al. 2011; Zhao et al. 2009). Some
contradictory reports suggest in turn that the R-enantiomer
of 2HG stimulates the activity of EGLN1 (PHD2), EGLN2
(PHD1), and to a lesser extent EGLN3 (PHD3) and thus
inhibit the activity of factor HIF-1. In contrast, the S-
enantiomer of 2HG has the capability of inhibiting PHDs
(Koivunen et al. 2012; Losman et al. 2013). However,
recent studies (Tarhonskaya et al. 2014) have shown that
under in vitro conditions, non-enzymatic oxidation of 2HG
to AKG may occur (involving reducing agents such as
ascorbic acid or the reduced form of L-glutathione), and the
level of AKG formed in this process is sufficient to activate
PHD2. The results of these studies may suggest a misin-
terpretation of the previous results (Koivunen et al. 2012),
but further studies are needed to determine accurately the
effect of 2HG on the activity of PHD2.
The Role of AKG and its Structural Analogues
in the Regulation of Epigenetic Processes
Chemical modifications of chromatin play an important
role in regulating the function of the genome and therefore,
in cell physiology. Information provided by epigenetic
modifications (changes made without modifying the DNA
sequence) plays a considerable part in regulating the pro-
cesses such as transcription or DNA repair and replication.
At the same time, the role of factors regulating epigenetic
processes is also very important, because changes in the
level of their expression or genomic changes in these fac-
tors may contribute to induction or maintenance of a
variety of tumours (Dawson and Kouzarides 2012). The
basic processes regulating chromatin structure and function
are DNA methylation and histone post-translational mod-
ification (acetylation, methylation, phosphorylation,
ubiquitination, biotinylation, and SUMOylation). Many
enzymes, including methyltransferases and demethylases,
are involved in these processes (Meng et al. 2015). Recent
studies indicate that AKG and its structural analogues—
succinate, fumarate, and 2HG can regulate the level of
DNA and histone methylation, as the main enzymes con-
ducting demethylation/hydroxylation reactions belong to
the family of 2-OGDD. The main demethylases of histones
are KDM2-7, which remove methyl groups from almost all
known methylation sites in histones and can also catalyse
the demethylation of three methylated lysines and arginines
(Hoffmann et al. 2012). In turn, the process of oxidative
DNA demethylation is conducted by TET1-3 hydroxylases,
which hydroxylate 5mC to 5-hmC (Ito et al. 2010; Tahil-
iani et al. 2009). Several studies (Cervera et al. 2009;
Chowdhury et al. 2011; Letouze´ et al. 2013; Schaap et al.
2013; Xiao et al. 2012; Xu et al. 2011) have shown that
both the Krebs cycle intermediate metabolites, succinate
and fumarate, and the R(-)2HG act as competitive inhi-
bitors of enzymes KDMs and TETs, and that the inhibitory
effect enhances methylation of DNA and histones by
methyltransferases, which in turn may increase carcino-
genesis. Nevertheless, the effect of these structural
analogues of AKG can be reversed by AKG itself.
Anti-Tumour Activity of Exogenous AKG: In Vitro
and In Vivo Studies
One of the very important elements of response to hypoxia
and HIF-1 activation is transcription of genes playing a key
role in angiogenesis. This process is crucial for the
development of solid tumours. The growing tumour tissue
needs high amounts of oxygen and nutrients that are sup-
plied by diffusion from the nearby blood vessels in the
initial stage of tumour development. As the tumour
develops and increases its size, the cells of the nearby
blood vessels start running out of oxygen, which activates
HIF-1 and initiates the process of neoangiogenesis. HIF-1
in tumour cells activates the transcription of genes for pro-
angiogenic factors such as vascular endothelial growth
factor (VEGF), PDGF-B (platelet-derived growth factor,
type B), hepatocyte growth factor, epidermal growth fac-
tor, angiopoietin-2, or placental growth factor (Sacewicz
et al. 2009). Matsumoto et al. (2006, 2009) showed that
exogenous AKG exhibited anti-tumour activity by reduc-
ing the level of the HIF-1a subunit and inhibition of
angiogenesis in hypoxic conditions. In their study, AKG
inhibited the expression of the HIF-1a subunit and the
ability to connect HIF-1 protein subunits, decreased the
activity of the Vegf gene promoter, and, consequently,
inhibited VEGF and erythropoietin production in the
Hep3B cell line. Furthermore, AKG inhibited tube for-
mation in an in vitro angiogenesis model. Those anti-
angiogenic effects of AKG were confirmed in another
in vitro study, carried out using the Lewis lung carcinoma
(LLC) cell line (Matsumoto et al. 2009). Additionally,
AKG administered alone showed anti-tumour activity and
enhanced the activity of a chemotherapeutic agent (5-flu-
orouracil, 5-FU) in vivo. In the mouse dorsal air sac assay,
AKG reduced the amount of newly formed blood vessels
caused by administration of the cancer cell line (LLC).
Also intraperitoneal administration of AKG alone or its
combination with 5-FU to mice with transplanted tumours
significantly inhibited tumour growth and angiogenesis in
tumour tissue (Matsumoto et al. 2009) which suggests the
clinical usefulness of this molecule. In turn, the results of
the experiments carried out by Brie`re et al. (2005) and
MacKenzie et al. (2007) suggest a possibility of application
of AKG in the treatment of neoplastic diseases in which
Krebs cycle enzyme defects cause pseudohypoxia and
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activation of HIF-1 in normoxia. Brie`re et al. (2005) have
shown that exogenous AKG prevented translocation of
HIF-1 into the nucleus of fibroblasts with a mutation in the
gene for SDHA (succinate dehydrogenase subunit A). In
another study, the MacKenzie et al. (2007) have shown that
the competitive inhibition of PHDs by succinate or fuma-
rate may be reversed by increasing the cellular level of
AKG. However, native AKG does not easily penetrate into
cells; therefore, to increase the effectiveness of its function,
tests were carried out using cell-permeating AKG deriva-
tives, i.e. AKG esters with increased hydrophobicity—
octyl-AKG and 1-trifluoromethyl benzyl-AKG (converted
by cytoplasmic esterases to AKG). These derivatives
restored the normal activity of PHDs, thereby decreasing
the level of HIF-1a in SDH-deficient cells (MacKenzie
et al. 2007). Other in vitro studies (Tennant et al. 2009)
have shown that AKG esters (1-trifluoromethyl benzyl-
AKG, TaAKG) can restore the activity of PHDs under
hypoxic conditions, which has far-reaching effects on
tumour cells. Restoration of the PHD activity in such
conditions not only resulted in destabilisation of HIF-1a,
but also induced functional changes in cells—reversal of
the hypoxia-induced increased glycolysis process and cell
death as its consequence. In addition, it has been shown
that AKG derivatives (TaAKG and ETAKG—5-ethyl,4-1-
trifluoromethylbenzyl AKG) may also function well
in vivo. TaAKG penetrated several layers of cells in
spheroids derived from cell line HCT116 (human colon
carcinoma) and destabilised their HIF-1a subunit. More-
over, after oral administration of ETAKG to a mouse
xenograft tumour model, increased levels of AKG within
the tumour tissues were observed, as well as decreased
levels of HIF-1a, and reduced glucose metabolism. The
results of the studies mentioned above suggest that AKG in
the form of a diester can reactivate PHDs and destabilise
HIF-1a in vivo, thereby reducing the expression of genes
targeted by this factor (Tennant et al. 2009). However, it
has recently been shown that not all types of AKG esters
that penetrate the cell membrane have the same activity on
HIF-1. In the studies of Hou et al. (2014), membrane
permeable ester dimethyl AKG (DAKG), which is the
precursor of AKG, temporarily stabilized HIF-1a by inhi-
bition of PHD2. During the long-term impact of DAKG on
cells under normoxia conditions, an increase in the level of
HIF-1a and expression of its target genes was observed,
which indicates that DAKG, in contrast to AKG, promotes
the state of pseudohypoxia. The authors speculate that at a
high availability of nutrients, DAKG may have been
quickly converted to succinate or fumarate, which inhibited
the activity of PHD2. On the other hand, the activity of
PHD2 might have been inhibited by increasing intracellu-
lar levels of ROS in pseudohypoxic conditions induced by
DAKG.
Additionally, in vitro studies have shown that exogenous
AKG may affect the level of DNA methylation (Letouze´
et al. 2013). In contrast to genetic mutations, DNA
methylation is a reversible process, which creates a pos-
sibility of introduction of new drugs for the treatment of
certain tumours (Rodrı´guez-Paredes and Esteller 2011).
Cancer cells are often characterised by a decrease in total
DNA methylation and by hypermethylation of promoter
CpG islands, which results in transcriptional silencing of
tumour suppressor genes. This phenotype, which is char-
acterised by simultaneous multiple gene hypermethylation,
occurs, for example, in glioma, in which it is the result of
mutations in IDH1/IDH2 genes and the inhibiting activity
of 2HG on enzymes belonging to the KDM and TET
groups. Also in paraganglioma, mutations in the SDH
genes determine such a phenotype (Letouze´ et al. 2013). In
the studies of Letouze´ et al. (2013), SDH-deficient chro-
maffin cells displayed an increased 5-mC/5-hmC ratio and
histone methylation, while the addition of AKG to the
culture medium reversed the accumulation of 5mC in vitro
and consequently changed this phenotype. These results
suggest that exogenous AKG can restore the TETs enzyme
activity inhibited by succinate accumulated in cells and
restore the cellular normal phenotype.
Given the contradictory results obtained in studies using
various esters of AKG, currently, it seems to be safer to use
AKG in its native form in cancer therapy. This is supported
by the fact that recent studies have shown an antiprolifer-
ative effect of AKG on three cancer cell lines: Caco-2, HT-
29, and LS-180, representing different stages of the
development of colon adenocarcinoma (Rzeski et al. 2012).
AKG interfered in the cell cycle of the tumour cells by
increasing the expression of cyclin-dependent kinase
(CDK) inhibitors p21 Waf/CIP1 and p27 Kip1. Affecting
the cell cycle by influencing the proteins involved in its
regulation (cyclins) is a very promising feature of AKG as
a potential anticancer agent. Each stage of the cell cycle is
supported by specific cyclins forming complexes with
CDKs, which are involved in phosphorylation of certain
proteins. This facilitates maintenance of the cycle, and
consequently leads to cell division. The above-mentioned
CDK inhibitors subsequently inhibit DNA replication and
are responsible for cell cycle arrest resulting in the absence
of cell division (Meeran and Katiyar 2008; Xiong et al.
1993). The influence of AKG on the cell cycle of tumour
cells is not limited to increasing the expression of the CDK
inhibitors. It also decreased the protein level of cyclin D1
and inhibited phosphorylation of the key regulator of the
cell cycle, i.e., the Rb protein, which resulted in arresting a
large number of cells in the G1 phase, preventing them
from entering the division phase (Rzeski et al. 2012).
It should be noted that AKG in combination with
5-hydroxymethylfurfural, prepared in the form of an
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infusion solution, are currently being investigated for the
treatment of patients with non-small-cell lung carcinoma,
not responding to any conventional therapy. This combi-
nation, named KARAL, is currently in phase II clinical
study and shows great promises as cancer treatment
(Donnarumma et al. 2013).
Conclusions
Since the discovery and description of the Krebs cycle, a
number of features and functions of one of its main
metabolites, i.e. AKG have been identified so far. Yet,
many of the AKG actions are still waiting to be discovered.
However, current knowledge about this metabolite already
ensures its practical application in various fields of human
life. Today, AKG is synthesised chemically, but attempts
have been made at biotechnological production of this
metabolite by various bacteria and yeast (Otto et al. 2011).
AKG is of particular importance in industry, where it is
used as a building material in the chemical synthesis of
heterocycles. It is also a major component of new
biodegradable, chemoselective, and mechanically
adjustable elastomers with a potential application in bio-
medicine (Barrett and Yousaf 2008). However, the
properties of this molecule also allow use thereof in med-
icine. AKG is used nowadays as a component of solutions
for infusion, formulations used in wound healing, or as a
dietary supplement. It is used, for example, during cardiac
operations in order to avoid disturbances of blood flow and
pressure (Kjellman et al. 1997) or in patients after surgery
or trauma to prevent muscle breakdown. Many studies
indicate that it may be helpful in the treatment of various
diseases and solving health problems, e.g., kidney disor-
ders, bacterial and yeast infections, problems with many
organs, such as the intestines, stomach, liver, eyes, and
even during cyanide intoxication. However, the efficiency
of the therapeutic use, in some cases, is still debated.
Broadly described, the positive effect of AKG on bone
tissue suggests its potential application in prevention of
bone formation disorders, in the treatment of diseases with
progressive loss of bone mass, such as osteoporosis, or in
improving the body’s bone mass. Nevertheless, the mech-
anism of its action on bone tissue has not been elucidated
yet.
Some studies from recent years have provided a lot of
new interesting information about the role of AKG as a
molecule regulating cell function, which may allow it to be
used in the treatment of cancer. Depending on the type of
cancer, AKG could affect tumour cells by reversing their
metabolic response to hypoxia or pseudohypoxia. The
antiproliferative activity of AKG suggests in turn the
possibility of restoring oxidative phosphorylation in
tumour cells in place of aerobic glycolysis, which is
characteristic to all cancers, in states of increased avail-
ability of this metabolite to tumour cells. However,
additional studies are required to confirm this hypothesis.
Additionally, for the therapeutic efficacy of AKG, it is also
important to determine which form of supplementation
would be the most applicable—oral administration, infu-
sion, or, e.g., administration of AKG in the form of
nanomolecules whose action is aimed specifically at the
tumour cells. Not until performing additional in vitro
studies and clinical trials could we evaluate the effective-
ness of AKG as an anticancer agent then. Nevertheless,
even the results of the already existing studies suggest a
possibility of using AKG, e.g., in chemoprevention or as a
support to anti-cancer therapy.
Recent studies suggest that AKG can also regulate the
ageing process of the organism and have an influence on
prolonging the lifespan (Chin et al. 2014; Salminen et al.
2014). Research performed in the next few years will
probably give us an answer to the question whether to
expand the characteristics of AKG with another feature,
which is maintaining the longevity.
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